Bladder Cancer

>

Latest News

UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC
UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

March 11th 2025

In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.

Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma
Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma

March 4th 2025

Outcomes observed in the phase 3 EV-302 trial are “transformative” for most patients with advanced or metastatic urothelial carcinoma.
EV-302 Supports Enfortumab Vedotin Plus Pembrolizumab as Bladder Cancer SOC

February 25th 2025

Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102
Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102

February 15th 2025

Data from the EV-302 trial support enfortumab vedotin plus pembrolizumab as a new standard of care in frontline urothelial cancer.
Enfortumab Vedotin Combo Improves PFS/OS Vs Chemo in Urothelial Carcinoma

February 15th 2025

More News